Physician profile
Cheryle Cutlip
NPI 1336171586
$2,019.97
in general payments reported to CMS, 2019-2025
35 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $174 · 2021: $19.16 · 2022: $241 · 2023: $385 · 2024: $356 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $198.26 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.64 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $189.09 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $187.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $146.76 | 2023-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $119.85 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $115.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $63.78 | 2019-2024 | Airsupra |
| Amgen INC. | $58.07 | 2019-2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $54.98 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $54.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $53.02 | 2019-2023 | Spravato, Xarelto |
| Edwards Lifesciences Corporation | $42.29 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dynavax Technologies Corporation | $41.68 | 2019-2023 | Heplisav-B |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $40.02 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2023 | |
| Novartis Pharmaceuticals Corporation | $33.73 | 2019-2020 | |
| Amarin Pharma, INC. | $29.98 | 2019-2020 | |
| Exact Sciences Corporation | $28.95 | 2023-2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $23.27 | 2023 | Zio Xt Patch |
| Organon LLC | $22.47 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.75 | 2025 | Gvoke Hypopen |
| Viiv Healthcare Company | $21.28 | 2024 | Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.07 | 2025 | Caplyta |
| Lundbeck LLC | $20.24 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $20.09 | 2024 | Thinprep 2000 Processor |
| Grifols USA, LLC | $19.75 | 2024 | Prolastin-C Liquid |
| Welch Allyn | $19.16 | 2021 | |
| Indivior INC. | $18.15 | 2023 | Sublocade |
| Strongbridge US INC. | $18.07 | 2019 | |
| Impel Pharmaceuticals INC. | $14.27 | 2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $12.62 | 2020 | |
| Antares Pharma, INC. | $12.20 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.88 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryle Cutlip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.